Vivoryon Therapeutics AG: Vivoryon Therapeutics Announces Outcome of Exclusive Option Deal with MorphoSys
DGAP-News: Vivoryon Therapeutics AG
/ Key word(s): Miscellaneous
Vivoryon Therapeutics Announces Outcome of Exclusive Option Deal with MorphoSys
Vivoryon will continue to evaluate QPCTL inhibitors in oncology based on preclinical studies conducted in collaboration with the University of Kiel and will consider strategic development options based on the existing proof-of-concept data
HALLE (SAALE) / MUNICH, Germany, 29 April 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced that MorphoSys has not exercised the exclusive option to license Vivoryon's small molecule QPCTL inhibitors in the immuno-oncology field.
During the option period, MorphoSys conducted preclinical studies to assess the potential of small molecule QPCTL inhibitors in oncology as well as the possible benefits of combining these inhibitors with MorphoSys' proprietary program, tafasitamab, a compound in late-stage development for the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). In parallel, Vivoryon, based on its 2019 research collaboration with the University Medical Center Schleswig-Holstein, Campus Kiel, conducted a similar series of preclinical studies.
Ultimately, the data demonstrated a significant additive effect when QPCTL inhibitors were combined with CD20 and other antibodies, indicating that Vivoryon's lead drug candidate, PQ912, could represent a novel approach for cancer therapy. Vivoryon's orally available compounds target the QPCTL enzyme, which has been shown to be a modulator of the CD47-SIRP alpha interaction. Left unchecked, this interaction allows cancer cells to escape the body's innate immune defense through inhibition of the phagocytic activity of macrophages.
29.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||Vivoryon Therapeutics AG|
|Phone:||+49 (0)345 555 9900|
|Fax:||+49 (0)345 555 9901|
|Listed:||Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam|
|EQS News ID:||1032183|
|End of News||DGAP News Service|